RCKT · Rocket Pharmaceuticals, Inc.

Current Thesis

Rocket Pharmaceuticals’ Danon recovery thesis requires clinical progress at the 2026-10-06 webinar and a weekly recovery above the 2026-09-04 reference close of $3.86 before a weekly close below $3.20. Rocket’s September 15 announcement supplies the dated clinical forum. Company release, 2026-09-15

The regulatory uncertainty identified in the September 6 research note has narrowed: Rocket reports Food and Drug Administration (FDA) alignment on continued dosing. As an inference, the narrative is maturing — the regulatory milestone arrived on September 15, but the September 18 market close of $3.37 remains below September 4’s $3.86. Regulatory progress has not yet established a price recovery. September 15 announcement

Bullish and bearish views on Rocket Pharmaceuticals, Inc.

The model's bull view on Rocket Pharmaceuticals, Inc. (RCKT), in brief: The pivotal framework remains intact. On 2026-09-15, Rocket reported a 12-patient pivotal population including the initial three modified-protocol patients, with established 12-month endpoints retained. This removes the previously unresolved question of whether those patients… The bear view: Safety evidence remains preliminary. The 2026-08-03 update reported no thrombotic microangiopathy or capillary leak syndrome among the initial three modified-protocol patients. The sample is too small to establish safety across the intended population or efficacy at the… Both cases follow in full.

Bull Case

• The pivotal framework remains intact. On 2026-09-15, Rocket reported a 12-patient pivotal population including the initial three modified-protocol patients, with established 12-month endpoints retained. This removes the previously unresolved question of whether those patients count toward the pivotal study. Company announcement
• Reported liquidity supports development. Rocket reported $283.7 million in cash, cash equivalents and investments at 2026-06-30 and projected funding into Q2 2028. That runway is management’s forecast; a subsequent disclosure shortening it would weaken this part of the case. Q2 results, 2026-08-10

Bear Case

• Safety evidence remains preliminary. The 2026-08-03 update reported no thrombotic microangiopathy or capillary leak syndrome among the initial three modified-protocol patients. The sample is too small to establish safety across the intended population or efficacy at the recalibrated dose. August 3 safety update
• The market has weakened. The supplied adjusted daily series records a $3.37 close on 2026-09-18, a three-month price decline of 2.6% and a 14-day relative strength index of 30.4. These observations do not establish a reversal.
• Proposed-sale notices have continued. Rocket’s filing index lists Form 144 notices dated 2026-09-11, 2026-09-14 and 2026-09-15, plus a September 15 Form 4 ownership-change filing. The index alone does not establish completed discretionary sales, quantities or motives. Company filing index

Setup & Price Structure

The September 18 close of $3.37 sits below the August 14 reference close of $3.47 and September 4’s $3.86, both documented in the September 6 research note. The recovery case uses $3.86 as its observable price outcome and retains the previously published $3.20 research boundary. Neither level is presented as newly verified technical support.

The evidence supports a low-conviction recovery forecast: price has weakened despite the regulatory development. Moving-average values, turnover, short interest and securities-borrow data are absent from the supplied September 18 snapshot, so distance above a rising average and crowded speculative participation cannot be established. Proposed-sale filings are observable positioning evidence; they do not establish that insider transactions caused the decline.

Catalyst Calendar (next 30 days)

• 2026-10-01 — Commercial window begins. This is the calendar opening of the Q4 2026 KRESLADI availability and patient-onboarding window guided on 2026-08-10, not a company-confirmed launch appointment. Failure to begin onboarding during that quarter would contradict the guidance. Q2 company release
• 2026-10-06 — Danon program webinar. Rocket scheduled the comprehensive program update for 4:30 p.m. Eastern Time. It provides a dated test of the clinical-progress thesis; the announcement does not guarantee human efficacy results. September 15 company release

What Would Change Our Mind

Loss of the existing research boundary ends the price-recovery case: a weekly close below $3.20 invalidates it. This preserves the condition published on September 6 rather than moving the threshold after the September 18 decline. A weekly close above the September 4 reference close of $3.86, accompanied by disclosed clinical progress, would satisfy the recovery case.

The small-cohort safety premise would separately fail if Rocket disclosed a new treatment-related serious adverse event or a dosing suspension. An October 6 presentation without additional clinical evidence would leave that premise unproven; regulatory agreement alone cannot demonstrate patient benefit.

Correlation Notes

This remains a single-name clinical setup. The September 18 evidence contains no paired biotechnology-index return series, so a correlation coefficient or claim that a sector move explains the decline is unsupported. The rare-disease and binary-catalyst tags describe the research subject; they do not establish common price behavior with other companies.